Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01818076 · ClinicalTrials.gov registry record · Phase 3
Open Label Study to Assess Long-term Safety of Repeat Administration of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines
A Phase 3 study, sponsored by Revance Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 311
- Enrollment target
NCT01818076 is a Phase 3 study that was terminated before completion, run by Revance Therapeutics. The registered enrollment target is 311 participants.
The verdict
NCT01818076, a Phase 3 study, was terminated before completion, sponsored by Revance Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 311 participants
- Enrollment target
Study Summary
This study will evaluate the long-term safety of botulinum toxin type A for the treatment of moderate to severe crow's feet lines after repeat application.
Interventions
- DRUG Botulinum Toxin Type A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 311 participants |
| Start Date | 2013-02 |
| Est. Completion | 2013-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01818076
The ClinicalTrials.gov registry entry for NCT01818076 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 311 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Revance Therapeutics, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Botulinum Toxin Type A is the first listed.
NCT01818076 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01818076 about?
NCT01818076 is a clinical study titled "Open Label Study to Assess Long-term Safety of Repeat Administration of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines". This study will evaluate the long-term safety of botulinum toxin type A for the treatment of moderate to severe crow's feet lines after repeat application.
What is the current status of trial NCT01818076?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 311 participants. The study started on 2013-02. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01818076?
The interventions under investigation include: Botulinum Toxin Type A (DRUG).
Who is sponsoring clinical trial NCT01818076?
This trial is sponsored by Revance Therapeutics, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.